260 related articles for article (PubMed ID: 30232022)
1. Association of high level of hs-CRP with in-stent restenosis: A case-control study.
Baktashian M; Saffar Soflaei S; Kosari N; Salehi M; Khosravi A; Ahmadinejad M; Moohebati M; Ebrahimi M; Rahmani F; Khameneh-Bagheri R; Ahmadi M; Sadabadi F; Tayefi M; Bazhdanzadeh S; Ferns GA; Hashemi SM; Pasdar A; Ghayour-Mobarhan M
Cardiovasc Revasc Med; 2019 Jul; 20(7):583-587. PubMed ID: 30232022
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
Zeng M; Yan X; Wu W
BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
[TBL] [Abstract][Full Text] [Related]
3. Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up.
Zhao C; Yang L; Mao L; Zhong L; Li X; Wei S
Coron Artery Dis; 2013 Aug; 24(5):357-60. PubMed ID: 23835667
[TBL] [Abstract][Full Text] [Related]
4. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
5. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
[TBL] [Abstract][Full Text] [Related]
6. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
Zhao K; Li YJ; Gao S
Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
[TBL] [Abstract][Full Text] [Related]
7. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
[TBL] [Abstract][Full Text] [Related]
9. Preprocedural red blood cell distribution width predicts bare metal stent restenosis.
Yildiz A; Tekiner F; Karakurt A; Sirin G; Duman D
Coron Artery Dis; 2014 Sep; 25(6):469-73. PubMed ID: 24614629
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
11. CHA
Zhao SG; Xu JJ; Tao ZH; Jin L; Liu Q; Zheng WY; Jiang LQ; Wang NF
J Int Med Res; 2019 Jun; 47(6):2533-2544. PubMed ID: 31039653
[TBL] [Abstract][Full Text] [Related]
12. Levels of plasma Quaking and cyclooxygenase-2 predict in-stent restenosis in patients with coronary artery disease after percutaneous coronary intervention.
Wang P; Kuang Y; Liu Y; Zhang Y; Gao H; Ma Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):739-747. PubMed ID: 35837773
[TBL] [Abstract][Full Text] [Related]
13. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
[TBL] [Abstract][Full Text] [Related]
14. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
15. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
[TBL] [Abstract][Full Text] [Related]
16. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
[TBL] [Abstract][Full Text] [Related]
17. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.
Cheng G; Chang FJ; Wang Y; You PH; Chen HC; Han WQ; Wang JW; Zhong NE; Min ZQ
Med Sci Monit; 2019 Jan; 25():240-247. PubMed ID: 30617247
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study.
Sabbah M; Kadota K; El-Eraky A; Kamal HM; Abdellah AT; El Hawary A
Int J Cardiovasc Imaging; 2017 Oct; 33(10):1463-1472. PubMed ID: 28444549
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
20. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
